Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | LMNA | P02545 | 8/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | SHBG | P04278 | 5/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.57 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159071 | 0.90 | ALDH1A1 (0.67) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| SCHEMBL927204 | 0.89 | SMN1; SMN2 (0.77) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| SCHEMBL19327125 | 0.89 | SMN1; SMN2 (0.77) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| SCHEMBL11211928 | 0.86 | NR3C2 (0.73) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| SCHEMBL11211930 | 0.86 | NR3C2 (0.73) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL18891475 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL13752803 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL21243062 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL4065 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT | |
| Desoxycorticosterone SCHEMBL15763287 | 0.83 | LMNA (1.00) | SMN1; SMN2LMNACYP3A4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0047016-B1 | PROGESTERONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-14 | — | — | EP | claimed |
| EP-0047016-A1 | Progesterone derivatives, process for their production, and pharmaceutical compositions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-03-10 | — | — | EP | claimed |
| US-4293548-A | DIURETICS, ALDOSTERONE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1981-10-06 | — | — | US | claimed |
| US-20140315808-A1 | INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY | MOR RESEARCH APPLICATIONS LTD. (IL) | 2014-10-23 | — | — | US | disclosed |
| EP-1937254-A2 | INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY | MOR RESEARCH APPLICATIONS LTD. (IL) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007013078-A2 | INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY | MOR RESEARCH APPLICATIONS LTD. (IL) | 2007-02-01 | — | — | WO | disclosed |
| US-20040037806-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | PHARMACIA CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-20030162759-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | disclosed |
| EP-0047016-B1 | PROGESTERONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-14 | — | — | EP | disclosed |
| EP-0047016-A1 | Progesterone derivatives, process for their production, and pharmaceutical compositions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-03-10 | — | — | EP | disclosed |
| US-4293548-A | DIURETICS, ALDOSTERONE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162759-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | NR3C2, SERPINA6, NR3C1 | SMN1; SMN2 4308/4885LMNA 1133/4885CYP3A4 1394/4885 |
| US-20040037806-A1 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | NR3C2, IL1RN, SERPINA6 | SMN1; SMN2 4298/4885LMNA 1055/4885CYP3A4 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.